1. EU Directive 2001/83/EC of 6 November 2001, amended by Directive 2003/63/EC of 25 June 2003 (Annex I, Part I, § 3.2.1.1.b)
2. Ibazatene K (2005) Biopharmaceuticals in France: overview 2004. LEEM, Paris
3. European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Guideline on comparability of medicinal products containing biotechnology derived proteins as active substance: non-clinical and Clinical Issues (2003). http://www.emea.europa.eu
4. Bouchet JL, Brunet P, Canaud B et al (2009) Guidelines for using the biosimilar Erythropoietin (EPO). Nephrology & Therapeutics 5:61–66
5. Sorgel F et al (2009) Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and Epoetin Alfa after a Comparator Multiple Subcutaneous Administrations. Pharmacology 83:122–30